2016 — FHI 360 acts as an independent third party to assess the quality of Sino-implant (II). A quality assurance evaluation and monitoring program was implemented by FHI 360 to verify that Sino-implant (II) meets lot release specifications for the product. These annual reports expand on the results from the quality assurance evaluation and monitoring that began in 2008.
Sino-implant (II)/Levoplant Overview
December 2018 — This brief is an overview of the Sino-implant (II) initiative and its impact. From 2007-2018, the project was at the forefront of increasing access to affordable, high-quality contraceptive implants in resource-limited settings. By expanding access to this more affordable implant, the initiative helped increase competition and reduce costs in the implant market.
Sino-implant (II): Dahua brochure
2017 — This product brochure provides an overview of Sino-implant (II), Shanghai Dahua Pharmaceuticals, Ltd.’s two-rod contraceptive implant. The product is sold under the global brand Levoplant as well as other trade names, including Femplant, Trust, and Zarin.
Quality Evaluation of Sino-Implant (II)
December 2012 — Sino-implant (II), a subdermal two-rod implant, has been available in China for more than 15 years and is also available in a growing number of African and Asian countries. To assess the quality of Sino-implant (II), a five-year quality evaluation and monitoring program was designed and implemented starting in 2008. The evaluation program includes an annual battery of tests to assess:
- Aspects of the active ingredient, levonorgestrel
- The quality of the final product (to detect the level of elements or substances that are part of the implant and to predict how the body will react to product contact)
- Packaging components
